OSP News

Federal Waiver to Prescribe Buprenorphine for Opioid Use Disorder Eliminated, New Training Requirement Announced

Posted: 07/11/2023

As part of the Consolidation Appropriations Act of 2023, the federal DATA-waiver, or X-waiver, has been removed, making it easier for clinicians to use buprenorphine to treat individuals with opioid use disorder (OUD).

This act enacted a new one-time, 8-hour training requirement for all DEA-registered practitioners on the treatment and management of patients with opioid or other substance use disorders. Beginning June 27, 2023, all DEA-registered and new medical practitioners are required to attest to completion of the training when renewing or completing an initial registration.

Click here for more information on this new requirement.

 

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.

x

OSP Technical Support